Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ients with evaluable GCase data, and 5 of the 6 patients without a clear increase were either in the lowest dose cohort or the cohort dosed least frequently. As expected in this short term study, the levels of relevant hematological markers of Gaucher disease remained stable.

Amicus has amended the protocol for the 6-month Phase 2 clinical trial of Plicera patients naive to ERT to include modified doses and dose regimens. Amicus expects the results of this study to be available in 2009. In addition, in the second half of 2008, the Company expects to initiate a longer-term study in individuals switching from ERT to Plicera.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic drug candidate being developed for the treatment of Pompe disease. At the ACMG meeting in March, clinical investigators presented encouraging results from an ex vivo response study in cells from patients with Pompe disease as well as three Phase 1 clinical trials of AT2220 in healthy volunteers. The ex vivo response study was designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells from these samples where then treated with AT2220. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T > G. Data from the Phase 1 trials in a total of 72 healthy volunteers showed that AT2220 was generally safe and well tolerated at all doses.

In the second quarter of 2008, Amicus plans to initiate a Phase 2 clinical trial of AT2220 in patients with Pompe disease. The Company also plans to consider the initiation of a clinical trial of AT2220-ERT combination treatment in Pompe patients later in 2008
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... DUBLIN , June 02, 2015 /PRNewswire/ ... has announced the addition of the ... Testing Market" report to their offering. ... analysis of the US immunoprotein diagnostic market, ... market shares, and strategic profiles of leading ...
(Date:6/3/2015)... -- Findings presented at the European Organization ... of NeuroOncology (EANO) and European Society for Medical Oncology ... that EDO-S101 is effective in models of human glioblastoma ... radiotherapy (RT). [ 1 ] ... that combines the DNA damaging effect of bendamustine with ...
(Date:6/3/2015)... 2015 On April 21, 2015, California ... Communications Committee (11-0) and indicates the legislature's desire to support ... , The Committee Chairman supports the bill and would like ... 8,000 GWh and would also like to see any new ... This “Wait List” and timing are extremely important. , To ...
(Date:6/3/2015)... 2015 Typical racks for laboratory freezers ... and depths often taking up unnecessary room in already ... Low 5 Box Freezer Racks offer a customizable ... freezer storage boxes and freezers. , “These racks ... experiments or multiple people because users can configure freezer ...
Breaking Biology Technology:United States Strategies in the Immunoprotein Diagnostic Testing Market Report 2015 2Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 2Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 3Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 4Bmark Energy Announces the Sign-up Deadline for Companies Interested in California’s Direct Access Program is June 12th, 2015 at 5:00pm. 2Freezer Space Can Now Be Configured Your Way with New Modular Freezer Racks 2
... , BEIJING, China , July 6 ... the development, assembly,marketing and sale of medical devices and homecare medical products in ... EPS for,fiscal year 2010. , , ... (Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO ) , ...
... Cellectis (Alternext: ALCLS), the French genome engineering specialist, announced today ... by Taconic Artemis and Taconic Farms Inc in December 2008 ... , , , ... of the Tribunal de Grande Instance decided on Tuesday, June 29 ...
... July 6 Novavax, Inc. (Nasdaq: NVAX ... M.D., as the company,s Chief Scientific Officer who will report ... Officer of Novavax.  Previously, Dr. Glenn was Chief Scientific Officer ... international health at Johns Hopkins University,s School of Public ...
Cached Biology Technology:Dehaier Medical Systems Reaffirms Earnings Estimate of $0.80 EPS for FY 2010 2Dehaier Medical Systems Reaffirms Earnings Estimate of $0.80 EPS for FY 2010 3Dehaier Medical Systems Reaffirms Earnings Estimate of $0.80 EPS for FY 2010 4Taconic's Litigation Contesting License Termination By Cellectis Is Dismissed 2Taconic's Litigation Contesting License Termination By Cellectis Is Dismissed 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 2Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 4
(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of the "Facial Recognition Market ... User - Global Forecast to 2020" report ... years, have seen facial recognition technology become more ... technology to gain traction and investment from the ...
(Date:5/27/2015)... , May 27, 2015   Codonics ... safety systems and image documentation solutions and ... comprehensive, technologically-advanced automation solutions, is pleased to ... The Codonics® Safe Label System® (SLS), an ... conjunction with the Omnicell Anesthesia Workstation, helps ...
(Date:5/25/2015)... 2015  Australia,s market for wearable technologies is considered ... the advent of several trials and prototypes. The release ... expected to ignite interest in wearables as well as ... . This in turn will spur greater innovation ... partnerships amongst vendors and distributors. Photo ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4
... . Vitamin B12 is vital for cell division, the ... system. Unable to produce the vitamin itself, the human body has ... known that on its way into the cell vitamin B12 is ... the cell interior with the aid of the transport protein CblF, ...
... Department of Energy,s Lawrence Berkeley National Laboratory (Berkeley Lab) found ... improved sperm DNA quality in older men. In younger men, ... DNA. In an analysis of 80 healthy male volunteers ... that men older than 44 who consumed the most vitamin ...
... California Institute of Technology (Caltech) have made the first-ever ... molecules one at a time. This new ... diseases, enable biologists to study viruses and probe the ... better measure nanoparticles and air pollution. The ...
Cached Biology News:Vitamin B12 deficiency: Tracing the causes 2Nutrition tied to improved sperm DNA quality in older men 2Nutrition tied to improved sperm DNA quality in older men 3Weighing molecules 1 at a time 2Weighing molecules 1 at a time 3Weighing molecules 1 at a time 4